Recently published 3D human and rat “pseudo-islets” display long-lived, robust metabolic activity, offer convenient solution for islet transplantation, anti-diabetic drug development, and assessment of acute and chronic toxicity of the endocrine pancreas.
InSphero AG today announced the launch of 3D InSight™ Human and Rat Pancreatic Microislets , further expanding the company’s catalog of organotypic 3D models produced using their patented hanging-drop production technology. The product launch follows InSphero‘s April publication of the microislets in the Journal of Tissue Engineering and Regenerative Medicine , characterizing their physiological properties and potential for use in islet transplantation, as well as a convenient in vitro model system for drug development and toxicity studies.
Primary human and rat pancreatic islets are widely used as in vitro models for diabetes and metabolic disorders, but current harvesting and isolation methods result in tissue impurities, size heterogeneity, and damage to cells that negatively impact the robustness of data ...